Discordance of KRAS Mutational Status between Primary Tumors and Liver Metastases in Colorectal Cancer: Impact on Long-Term Survival Following Radical Resection.
KRAS discordance
KRAS mutation status
colorectal liver metastases
colorectal tumor
overall survival
precision medicine
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Apr 2021
29 Apr 2021
Historique:
received:
28
03
2021
revised:
21
04
2021
accepted:
27
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
If KRAS mutation status of primary colorectal tumor is representative of corresponding colorectal liver metastases (CRLM) mutational pattern, is controversial. Several studies have reported different rates of KRAS discordance, ranging from 4 to 32%. Aim of this study is to assess the incidence of discordance and its impact on overall survival (OS) in a homogenous group of patients. KRAS mutation status was evaluated in 107 patients resected for both primary colorectal tumor and corresponding CRLM at the same institution, between 2007 and 2018. Discordance rate was 15.9%. Its incidence varied according to the time interval between the two mutation analyses (
Identifiants
pubmed: 33946899
pii: cancers13092148
doi: 10.3390/cancers13092148
pmc: PMC8125529
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Mol Pathol. 2003 Jun;56(3):137-40
pubmed: 12782759
Nat Med. 2015 Jul;21(7):795-801
pubmed: 26030179
Oncologist. 2008 Dec;13(12):1270-5
pubmed: 19056857
Cancer. 2014 Dec 15;120(24):3965-71
pubmed: 25155157
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164324
Br J Surg. 2018 May;105(6):618-627
pubmed: 29579319
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Ann Surg. 2011 Jun;253(6):1069-79
pubmed: 21451388
ESMO Open. 2018 May 5;3(4):e000353
pubmed: 29765773
Lancet Oncol. 2020 Mar;21(3):398-411
pubmed: 32014119
N Engl J Med. 2013 Sep 12;369(11):1023-34
pubmed: 24024839
Cancer Chemother Pharmacol. 2010 Aug;66(3):605-9
pubmed: 20361188
Clin Cancer Res. 2008 Aug 1;14(15):4830-5
pubmed: 18676755
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Surg. 2013 Oct;258(4):619-26; discussion 626-7
pubmed: 24018645
J Clin Oncol. 2008 Sep 1;26(25):4217-9
pubmed: 18757341
Br J Cancer. 2006 Apr 10;94(7):982-99
pubmed: 16538219
Cancer Biol Ther. 2018 Aug 3;19(8):659-663
pubmed: 29580164
J Gastrointest Surg. 2019 Oct;23(10):1957-1963
pubmed: 30276588
J Surg Oncol. 2009 Dec 1;100(7):538-45
pubmed: 19722234
J Gastrointest Surg. 2013 Feb;17(2):352-9
pubmed: 23225196
Surgery. 2019 Apr;165(4):712-720
pubmed: 30482518
JAMA Oncol. 2019 Mar 1;5(3):343-350
pubmed: 30476968
Br J Cancer. 2011 Mar 15;104(6):1020-6
pubmed: 21364579
Br J Cancer. 2009 Apr 7;100(7):1087-94
pubmed: 19293803
J Pathol. 2010 Jul;221(3):308-19
pubmed: 20527024
Br J Cancer. 2013 Jan 15;108(1):115-20
pubmed: 23175150
Eur J Surg Oncol. 2017 May;43(5):875-883
pubmed: 28302330
Ann Surg. 2019 Jan;269(1):120-126
pubmed: 28549012
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
Future Oncol. 2014 Apr;10(5):713-23
pubmed: 24799053
EBioMedicine. 2019 Feb;40:363-374
pubmed: 30733075
Oncotarget. 2018 Sep 28;9(76):34279-34288
pubmed: 30344942
Eur J Surg Oncol. 2018 Jan;44(1):80-86
pubmed: 29183640
Ann Surg. 2008 Jan;247(1):125-35
pubmed: 18156932
Hum Mol Genet. 2004 Oct 1;13(19):2303-11
pubmed: 15294875
Med Oncol. 2016 Jul;33(7):71
pubmed: 27270901
J Am Coll Surg. 2010 May;210(5):744-52, 752-5
pubmed: 20421043
Lancet Oncol. 2011 Jun;12(6):594-603
pubmed: 21163703
J Am Coll Surg. 2008 Mar;206(3):496-502
pubmed: 18308221
Surgery. 2013 Jun;153(6):801-10
pubmed: 23701876
Nat Commun. 2016 Dec 08;7:13665
pubmed: 27929064